One in every 8 men will develop prostate cancer in his lifetime. For Black men, this number increases to one in 6.
When caught early, 99% of men with prostate cancer will live for at least 5 years.
Each year, one in 200 men ages 55-69 has a prostate biopsy in VA. Two-thirds of these are negative for prostate cancer.
Prostate Cancer, Genetic Risk, & Equitable Screening Study (ProGRESS)
If you are a male U.S. Veteran between the ages of 55-69 and have never had prostate cancer or a prostate biopsy, you may be eligible to participate in the ProGRESS Study. By enrolling, you may help researchers better understand and potentially improve prostate cancer screening for Veterans.
ProGRESS is a nationwide clinical trial conducted by the U.S. Department of Veterans Affairs that looks at whether your genetic information can improve the way you are screened for prostate cancer.
Join ProGRESS in three easy steps
Enroll today, by clicking on our intake survey.
Provide a saliva sample using a collection kit delivered to your home.
Receive prostate cancer screening information.
The ProGRESS Study aims to use genetic testing to develop a personalized approach to prostate cancer screening for each man. This approach will identify men at high risk of prostate cancer who need screening and men at low risk who may not.
© 2024 ProGRESS. All rights reserved. Unless otherwise specified, all product names, service names, and logos appearing in this website are trademarks owned by or licensed to ProGress, U.S. Department of Veteran Affairs, its subsidiaries, or its affiliates. No use of any trademark, trade name, or trade dress in this website may be made without the prior written authorization, except to identify this study or it’s services.